中芯國際(00981.HK)升6.6% 傳華為Mate 60 Pro採用中芯先進工藝
中芯國際(00981.HK)今日(4日)高開1.5%,午後升幅擴大,有傳華為新手機Mate 60 Pro的晶片採用中芯N+2 7nm工藝技術,中芯現報21元,升6.6%,成交9,554.89萬股,涉資19.55億元。
早前華為在中國推出Mate 60 Pro,設備的細節包括海思最新的5G處理器麒麟9000(Hi36A0)。行業觀察機構TechInsights即將發表華為Mate 60 Pro的技術分析及評論,若確認Mate 60 Pro是使用中芯先進的N+2 7nm(集成SRAM緩存)及5G射頻前端晶片組,這將會是中國晶片行業的一個重大突破。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.